Recent advances in the treatment of presbyopia have focused on pharmacological agents as a novel therapeutic strategy that offers noninvasive, reversible options capable of enhancing depth of focus without altering the natural lens structure. As new and emerging pharmacological therapies...

This online, on-demand virtual symposium brings together renowned experts in neovascular retinal diseases, including nAMD and DME. In this educational program, these experts use a case-based format to discuss the latest data regarding effective management of these disorders, share their...

Macular telangiectasia type 2 (MacTel) is a rare, progressive retinal disease characterized by neurodegenerative changes, localized retinal degeneration, and alterations in the retinal vasculature. It usually presents bilaterally and leads to gradual central vision loss, and its early signs and...

Patients with diabetic retinopathy (DR) or diabetic macular edema (DME) tend to have a host of comorbidities and a considerable burden of required treatments and medical appointments. Recent additions to treatment options for DR and DME provide opportunities to reduce...

Join leading optometrists and ophthalmologists for two days of high-impact education, real-world clinical insights, and meaningful collaboration at EyeCon 2026, taking place September 26–27 at the Margaritaville Hollywood Beach Resort in Hollywood, Florida. Designed for today’s eye care professionals, EyeCon...